NACSELD慢加急性肝衰竭(NACSELD-ACLF)评分预测住院肝硬化患者30天生存
研究在14个北美三级肝病中心前瞻性纳入2675例非择期住院肝硬化患者,随机按60%/40%分为训练组(1605例)和验证组(1070例),验证NACSELD-ACLF评分(≥2个肝外器官衰竭)对30天生存(院内死亡或临终关怀出院)的预测能力。多变量模型显示,在控制入院年龄、白细胞计数、血清白蛋白、MELD评分和感染后,NACSELD-ACLF评分是生存下降的最强预测因子。
要点
- NACSELD-ACLF评分定义为≥2个肝外器官衰竭,作为床旁工具预测住院肝硬化患者30天生存。
- 在控制年龄、白细胞、白蛋白、MELD评分和感染后,该评分是生存下降的最强预测因子。
- 训练组c-statistic为0.8073,验证组为0.8532。
核心结论
- 尽管感染状态仍是死亡的重要预测因子,NACSELD-ACLF在独立的大规模多国前瞻性队列中被验证为简单、可靠的床旁工具,可预测感染和未感染住院肝硬化患者的30天生存。
研究设计与样本
- 研究使用北美终末期肝病研究联盟(NACSELD)数据库,包含14个三级肝病中心前瞻性纳入的非择期住院肝硬化患者(n=2675)。
- 队列随机按60%/40%分为训练组(n=1605)和验证组(n=1070)。
- 评估的器官衰竭包括:休克、肝性脑病(III/IV级)、肾衰竭(需透析)和呼吸衰竭(需机械通气)。
主要发现
- 患者最常见为白人(79%)、男性(62%),平均年龄57岁,酒精性肝硬化占45%,1079例患者在住院期间有感染。
- 平均MELD评分为19,Child评分中位数为10,两个拆分组之间无人口学差异。
- 多变量模型显示,在控制入院年龄、白细胞计数、血清白蛋白、MELD评分和感染后,NACSELD-ACLF评分(由器官衰竭数量确定)是生存下降的最强预测因子。
- 训练组c-statistic为0.8073,验证组c-statistic为0.8532。
临床怎么用
- 作者认为NACSELD-ACLF评分可作为简单、可靠的床旁工具,用于预测感染和未感染住院肝硬化患者的30天生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The North American Consortium for the Study of End-Stage Liver Disease's definition of acute-on-chronic liver failure (NACSELD-ACLF) as two or more extrahepatic organ failures has been proposed as a simple bedside tool to assess the risk of mortality in hospitalized patients with cirrhosis. We validated the NACSELD-ACLF's ability to predict 30-day survival (defined as in-hospital death or hospice discharge) in a separate multicenter prospectively enrolled cohort of both infected and uninfected hospitalized patients with cirrhosis. We used the NACSELD database of 14 tertiary care hepatology centers that prospectively enrolled nonelective hospitalized patients with cirrhosis (n = 2,675). The cohort was randomly split 60%/40% into training (n = 1,605) and testing (n = 1,070) groups. Organ failures assessed were (1) shock, (2) hepatic encephalopathy (grade III/IV), (3) renal (need for dialysis), and (4) respiratory (mechanical ventilation). Patients were most commonly Caucasian (79%) men (62%) with a mean age of 57 years and a diagnosis of alcohol-induced cirrhosis (45%), and 1,079 patients had an infection during hospitalization. The mean Model for End-Stage Liver Disease score was 19, and the median Child score was 10. No demographic differences were present between the two split groups. Multivariable modeling revealed that the NACSELD-ACLF score, as determined by number of organ failures, was the strongest predictor of decreased survival after controlling for admission age, white blood cell count, serum albumin, Model for End-Stage Liver Disease score, and presence of infection. The c-statistics were 0.8073 for the training set and 0.8532 for the validation set. CONCLUSION: Although infection status remains an important predictor of death, NACSELD-ACLF was independently validated in a separate large multinational prospective cohort as a simple, reliable bedside tool to predict 30-day survival in both infected and uninfected patients hospitalized with a diagnosis of cirrhosis. (Hepatology 2018;67:2367-2374).
引用
- O'Leary JG, Reddy KR, Garcia-Tsao G, et al. NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. Hepatology. 2018. PMID: 29315693. doi:10.1002/hep.29773
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。